he article outlines the positive impact of apabetalone in the investigator-led pulmonary arterial hypertension (PAH) pilot study, APPRoAcH-p

Rakovina Therapeutics presentation will highlight pre-clinical research related to its novel kt-4000 series.

A further five sites in Brazil and a third Canadian site, in Toronto, Ontario, will also be coming on line soon.

Enrollment and dosing of patients has commenced in a Phase 2b study at a site at the University of Alberta Hospital in Edmonton.

Funding will support the development of new research infrastructure for screening and optimization of potential drug candidates...

RVX will be hosting a corporate update webcast and conference call on Thursday, December 16th, 2021 at 2:00 pm MST.

Rakovina has been selected to join a three year US$975,000 (CDN1,297,000) research program funded by the St. Baldrick’s Foundation..

This initiative will provide the necessary investments to advance apabetalone for potential treatment of Covid in the Arab-African Economy

Apabetalone is the only drug of its class with a well-established safety record in human clinical trials...

Rakovina has been invited to present at the 6th biennial Canadian Cancer Research Conference which is being held virtually Nov. 8-11, 2021.